Charles Antoine Janssen shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors. Charles Antoine Janssen is vice chair of UCB, a global biopharmaceutical company headquartered in Belgium. And he's also managing partner of Kois https://koisinvest.com and Healthquad. Charles Antoine has experience in fundraising for social impact funds as well as investing the money raised in companies that want to solve societal problems. He shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors.
https://www.ucb.com
https://healthquad.in
All content for Health Innovation and Entrepreneurship is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Charles Antoine Janssen shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors. Charles Antoine Janssen is vice chair of UCB, a global biopharmaceutical company headquartered in Belgium. And he's also managing partner of Kois https://koisinvest.com and Healthquad. Charles Antoine has experience in fundraising for social impact funds as well as investing the money raised in companies that want to solve societal problems. He shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors.
https://www.ucb.com
https://healthquad.in
Using tampons for STI diagnosis and pain period treatment. Valentina is founder and CEO of Daye. She holds a bachelor’s degree in Business, Economics and Law, and a Master of International and Trade Law from the University of Buckingham, and she is currently working toward her Master of Public Health at Imperial College London. Prior to founding Daye, Valentina managed the artificial intelligence and machine learning portfolio at the Founders Factory, a start-up accelerator in London, and was a Venture Associate at the global investment company Techstars.
In 2018, after about 180 pitches to investors, Valentina raised £4 million in seed funding and Daye could start on its mission to remove the pain, shame and time wasted by women who are seeking relief from period pain. In 2020, Daye launched its first consumer product: a pain-relieving tampon to help around 90% of women who experience period pain. In 2023, Valentina raised another £10 million in series A funding for Daye. And Daye is now introducing its Diagnostic Tampon, aimed at the detection of sexually transmitted infections (STIs).
MSc in International Health and Tropical Medicine (IHTM) - https://www.tropicalmedicine.ox.ac.uk/study-with-us/msc-ihtm
Health Innovation and Entrepreneurship
Charles Antoine Janssen shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors. Charles Antoine Janssen is vice chair of UCB, a global biopharmaceutical company headquartered in Belgium. And he's also managing partner of Kois https://koisinvest.com and Healthquad. Charles Antoine has experience in fundraising for social impact funds as well as investing the money raised in companies that want to solve societal problems. He shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors.
https://www.ucb.com
https://healthquad.in
